Protocol Ledger

NCT04266795 · Phase II · COMPLETED

A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy

Interventional Phase II clinical trial protocol NCT04266795 sponsored by Takeda in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-10-13 Enrollment: 164 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04266795
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)164 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04266795
Protocol FieldVerified Registry Value
NCT IdentifierNCT04266795
Consolidated Lead SponsorTakeda
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment164 participants (ACTUAL)
Registered Start Date2020-10-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI